EPB41L4A: A promising drug target and biomarker for treating anemia

Target Name: EPB41L4A

NCBI ID: G64097

EPB41L4A

EPB41L4A: A promising drug target and biomarker for treating anemia

Anemia is a common disorder that affects millions of people worldwide, regardless of their age, gender, or underlying health conditions. Anemia is a condition where there is a decrease in the number of red blood cells or the amount of hemoglobin in the blood. Hemoglobin is the protein in red blood cells that carries oxygen from the lungs to the rest of the body. When the amount of hemoglobin in the blood is reduced, the body's tissues and organs may not receive enough oxygen, leading to a range of symptoms, including fatigue, weakness, shortness of breath, and dizziness.

EPB41L4A, a protein located on the surface of erythrocytes (red blood cells), has been identified as a potential drug target and biomarker for treating anemia. In this article, we will discuss the biology of anemia, the potential mechanisms by which EPB41L4A can contribute to anemia, and the research being done to investigate its potential as a drug.

biology of anemia

Anemia is a condition where there is a decrease in the number of red blood cells or the amount of hemoglobin in the blood. Hemoglobin is the protein in red blood cells that carries oxygen from the lungs to the rest of the body. When the amount of hemoglobin in the blood is reduced, the body's tissues and organs may not receive enough oxygen, leading to a range of symptoms, including fatigue, weakness, shortness of breath, and dizziness.

Anemia can be caused by a variety of factors, including iron deficiency, vitamin deficiency, chronic illness, and blood loss. Iron deficiency is the most common cause of anemia, particularly in women of childbearing age. Iron is essential for the production of hemoglobin, so when the body lacks iron, it cannot produce enough to meet its needs. Vitamin deficiency, such as vitamin B12, can also cause anemia. Chronic illness, such as kidney disease or rheumatoid arthritis, can also contribute to anemia. Blood loss, such as in surgery or injury, can also cause anemia.

EPB41L4A, a protein located on the surface of erythrocytes, has been identified as a potential drug target and biomarker for treating anemia.

The protein EPB41L4A is located on the surface of erythrocytes, which are the cells that carry oxygen from the lungs to the rest of the body. The protein is a member of the band 4.1 family of proteins, which are known as erythrocyte membrane proteins (EMPs). EMPs are involved in a variety of functions in the cell, including signal transduction and cell adhesion.

EPB41L4A has been shown to be involved in the regulation of hemoglobin (Hb) levels in the body. Hb is the protein in red blood cells that carries oxygen from the lungs to the rest of the body. When the amount of Hb in the blood is reduced, the body's tissues and organs may not receive enough oxygen, leading to anemia.

Potential mechanisms by which EPB41L4A can contribute to anemia

EPB41L4A has been shown to be involved in the regulation of hemoglobin (Hb) levels in the body. Hb is the protein in red blood cells that carries oxygen from the lungs to the rest of the body. When the amount of Hb in the blood is reduced, the body's tissues and organs may not receive enough oxygen, leading to anemia.

One potential mechanism by which EPB41L4A can contribute to anemia is through its role in the regulation of Hb production. The body needs Hb to produce hemoglobin, which is responsible for carrying oxygen from the lungs to the rest of the body. If the body does not have enough Hb, it may not be able to produce enough hemoglobin to meet its needs, leading to anemia.

Another potential mechanism by which EPB41L4A can contribute to

Protein Name: Erythrocyte Membrane Protein Band 4.1 Like 4A

The "EPB41L4A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EPB41L4A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets